Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone

ConditionPost Traumatic Stress Disorder

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-65

SponsorGlobal Coalition for Adaptive Research

About this trial

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.

Intervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Intervention B Vilazodone Hydrochloride (HCl)
Intervention B Placebo

Treatment groups

200 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Global Coalition for Adaptive Research

Lead sponsor

U.S. Army Medical Research and Development Command

Collaborator

PPD Development, LP

Collaborator

Berry Consultants

Collaborator

Idorsia Pharmaceuticals Ltd.

Collaborator

Cambridge Cognition Ltd

Collaborator

Citeline

Collaborator

Source ClinicalTrials.gov